Document ID: chunk:federal_register_of_legislation:F2025C00119:clause:3_1:p3
Version: federal_register_of_legislation:F2025C00119
Segment Type: clause
Provision Reference: sch 3 cl 1 (pt 3/69)
Character Range: 183410–194573

of RAS wild‑type metastatic colorectal cancer; AND
                                                                                                                Patient must not have progressive disease; AND
                                                                                                                The treatment must be in combination with first‑line chemotherapy; AND
                                                                                                                The treatment must be the sole PBS‑subsidised anti‑EGFR antibody therapy for this condition.
                                                                                                                Patients who have progressive disease on cetuximab are not eligible to receive PBS‑subsidised panitumumab.
                                                                                                                Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS‑subsidised panitumumab.
C5526               P5526          Panitumumab                                                                  Metastatic colorectal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures ‑ Streamlined Authority Code 5526
                                                                                                                Initial Treatment
                                                                                                                Patient must have RAS wild‑type metastatic colorectal cancer; AND
                                                                                                                Patient must have a WHO performance status of 0 or 1; AND
                                                                                                                The condition must be previously untreated; AND
                                                                                                                The treatment must be in combination with first‑line chemotherapy; AND
                                                                                                                The treatment must be the sole PBS‑subsidised anti‑EGFR antibody therapy for this condition.
                                                                                                                Patients who have progressive disease on cetuximab are not eligible to receive PBS‑subsidised panitumumab.
                                                                                                                Patients who have developed intolerance to cetuximab of a severity necessitating permanent treatment withdrawal are eligible to receive PBS‑subsidised panitumumab.
C5597                              Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain  Primary and relapsing superficial urothelial carcinoma of the bladder
                                   Mycobacterium bovis (Bacillus Calmette and Guerin), Tice strain
C5743                              Ondansetron                                                                  Nausea and vomiting
                                                                                                                The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

C5778                              Ondansetron                                                                  Nausea and vomiting
                                                                                                                The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.

C5805                              Palonosetron                                                                 Nausea and vomiting
                                                                                                                The condition must be associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy administration.
C5973                              Folinic acid                                                                 Megaloblastic anaemias
                                                                                                                The condition must be a result of folic acid deficiency from the use of folic acid antagonists.
C5997               P5997          Arsenic                                                                      Acute promyelocytic leukaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Authority Required procedures ‑ Streamlined Authority Code 5997
                                                                                                                The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR‑alpha fusion gene transcript.
C6018               P6018          Arsenic                                                                      Acute promyelocytic leukaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Authority Required procedures ‑ Streamlined Authority Code 6018
                                                                                                                Induction and consolidation treatment
                                                                                                                The condition must be characterised by the presence of the t(15:17) translocation or PML/RAR‑alpha fusion gene transcript.
C6106               P6106          Paclitaxel, nanoparticle albumin‑bound                                       Metastatic breast cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures ‑ Streamlined Authority Code 6106
C6119               P6119          Paclitaxel, nanoparticle albumin‑bound                                       HER2 positive breast cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures ‑ Streamlined Authority Code 6119
C6224                              Bleomycin                                                                    Lymphoma
C6247                              Idarubicin                                                                   Acute myelogenous leukaemia (AML)
C6265                              Cladribine                                                                   Hairy cell leukaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Compliance with Authority Required procedures ‑ Streamlined Authority Code 6265
C6266               P6266          Fluorouracil                                                                 Patients requiring administration of fluorouracil by intravenous infusion
C6275                              Bleomycin                                                                    Germ cell neoplasms
                    P6276